The evaluation of minimal/measurable disease in acute myeloblastic leukemia by flow cytometry is applicable to all patients. This is especially true when the samples are compared to normal bone marrow. Only a few strategies have been fully published allowing for translation to other laboratories. This fact and the diversity of panels used make harmonization difficult. The European LeukemiaNet proposal of core markers and the recent development of unsupervised analysis could make things more feasible in the near future.